Nanotherapeutics will conduct studies to develop an improved formulation of diethylenetriaminepentaacetate (DTPA) and improve manufacturing its processes.
DTPA can bind radioactive molecules to help the body remove them thereby treating people who have taken in radioactive particles.
The improved formulation, NanoDTPA is being developed as a short-term treatment for people exposed to radioactive elements like americium, curium, or plutonium.
DTPA should be administered intravenously or by nebulizer, as per the US Food and Drug Administration